🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,441
Drugs tracked
4,077

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

12 results for “Kymera Therapeutics” Clear

  1. KT-621

    Kymera Therapeutics

    Atopic Dermatitis

    phase 2 small molecule active

    2 trials

  2. KT-621

    Kymera Therapeutics

    Eosinophilic Asthma

    phase 2 small molecule active

    1 trial

  3. KT-621, KT-621, KT-621, The placebo is used in the Double-blind, Placebo-controlled (DBPC) Treatment Period. Participants are randomly assigned to receive either KT-621 or a matching placebo. The placebo is designed to match the study drug in appearance and administration method to maintain blinding.

    Kymera Therapeutics

    Moderate to Severe Atopic Dermatitis

    phase 2 small molecule active

    1 trial

  4. KT-621, Placebo oral tablet matched to KT-621, KT-621, KT-621

    Kymera Therapeutics

    Uncontrolled Moderate to Severe Eosinophilic Asthma

    phase 2 small molecule active

    1 trial

  5. SAR444656 (KT-474)

    Kymera Therapeutics

    Hidradenitis Suppurativa

    phase 2 small molecule terminated

    1 trial

  6. SAR444656 (KT-474)

    Kymera Therapeutics

    Atopic Dermatitis

    phase 2 small molecule terminated

    1 trial

  7. KT-253

    Kymera Therapeutics

    Myeloid Malignancies

    phase 1 small molecule completed

    1 trial

  8. KT-333

    Kymera Therapeutics

    Non Hodgkin Lymphoma (NHL)

    phase 1 small molecule completed

    1 trial

  9. KT-413

    Kymera Therapeutics

    Non Hodgkin Lymphoma

    phase 1 small molecule completed

    1 trial

  10. KT-474/Placebo

    Kymera Therapeutics

    Healthy Volunteer

    phase 1 small molecule completed

    1 trial

  11. KT-579

    Kymera Therapeutics

    Healthy Participants

    phase 1 small molecule active

    1 trial

  12. KT-621

    Kymera Therapeutics

    Healthy Participants Study

    phase 1 small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources